View Future GrowthMariMed 過去の業績過去 基準チェック /06MariMedの収益は年間平均-61.9%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間23.4% 10.2%割合で 増加しています。主要情報-61.87%収益成長率-62.47%EPS成長率Pharmaceuticals 業界の成長23.06%収益成長率10.22%株主資本利益率-23.84%ネット・マージン-7.90%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • May 14First quarter 2026 earnings released: US$0.01 loss per share (vs US$0.014 loss in 1Q 2025)First quarter 2026 results: US$0.01 loss per share (improved from US$0.014 loss in 1Q 2025). Revenue: US$39.5m (up 4.0% from 1Q 2025). Net loss: US$3.79m (loss narrowed 31% from 1Q 2025). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 42% per year, which means it has not declined as severely as earnings.お知らせ • Apr 16MariMed Inc. to Report Q1, 2026 Results on May 13, 2026MariMed Inc. announced that they will report Q1, 2026 results After-Market on May 13, 2026Reported Earnings • Mar 13Full year 2025 earnings released: US$0.037 loss per share (vs US$0.032 loss in FY 2024)Full year 2025 results: US$0.037 loss per share (further deteriorated from US$0.032 loss in FY 2024). Revenue: US$159.8m (up 1.2% from FY 2024). Net loss: US$14.5m (loss widened 19% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.お知らせ • Feb 11MariMed Inc. to Report Q4, 2025 Results on Mar 11, 2026MariMed Inc. announced that they will report Q4, 2025 results After-Market on Mar 11, 2026お知らせ • Sep 29MariMed Inc. to Report Q3, 2025 Results on Nov 05, 2025MariMed Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2025Reported Earnings • Aug 08Second quarter 2025 earnings released: US$0.003 loss per share (vs US$0.004 loss in 2Q 2024)Second quarter 2025 results: US$0.003 loss per share (improved from US$0.004 loss in 2Q 2024). Revenue: US$39.6m (down 2.0% from 2Q 2024). Net loss: US$1.27m (loss narrowed 23% from 2Q 2024). Revenue is forecast to grow 9.8% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.すべての更新を表示Recent updatesReported Earnings • May 14First quarter 2026 earnings released: US$0.01 loss per share (vs US$0.014 loss in 1Q 2025)First quarter 2026 results: US$0.01 loss per share (improved from US$0.014 loss in 1Q 2025). Revenue: US$39.5m (up 4.0% from 1Q 2025). Net loss: US$3.79m (loss narrowed 31% from 1Q 2025). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 42% per year, which means it has not declined as severely as earnings.お知らせ • Apr 25MariMed Inc., Annual General Meeting, Jun 04, 2026MariMed Inc., Annual General Meeting, Jun 04, 2026.お知らせ • Apr 16MariMed Inc. to Report Q1, 2026 Results on May 13, 2026MariMed Inc. announced that they will report Q1, 2026 results After-Market on May 13, 2026Buy Or Sell Opportunity • Apr 06Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 35% to CA$0.085. The fair value is estimated to be CA$0.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.6% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 7.8% per annum. Earnings are also forecast to grow by 19% per annum over the same time period.Reported Earnings • Mar 13Full year 2025 earnings released: US$0.037 loss per share (vs US$0.032 loss in FY 2024)Full year 2025 results: US$0.037 loss per share (further deteriorated from US$0.032 loss in FY 2024). Revenue: US$159.8m (up 1.2% from FY 2024). Net loss: US$14.5m (loss widened 19% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.お知らせ • Feb 11MariMed Inc. to Report Q4, 2025 Results on Mar 11, 2026MariMed Inc. announced that they will report Q4, 2025 results After-Market on Mar 11, 2026お知らせ • Feb 06MariMed's Eddies Introduces New Limited-Edition Valentine's Seasonal, Berry in Love BettyBetty's Eddies is expanding its lineup with a new limited-edition batch of strawberry chocolate chews in time for Valentine's Day: Berry In Love Betty. Betty's Eddies is one of the top-selling and award-winning brands developed and distributed by leading multi-state cannabis operator, MariMed Inc. Now available at MariMed's Thrive Dispensary locations and other cannabis retailers throughout Massachusetts, Maryland, Illinois, and Delaware, each libido-enhancing Berry In Love Bettychew is infused with full-spectrum cannabis, CBG, and horny goat weed, an herb used in China that may help increase blood flow and sexual function. All Betty's Eddie chews are vegan, gluten-free, and dairy-free. Berry In Love Betty chews stand out as the brand's first swirled chew, combining an eye-catching presentation with all-natural ingredients made from organic fruits and chocolate. Berry In Love Betty joins a full slate of Betty's Eddies products that feature specific end-effects, including Bedtime Betty's for restful nights, Take It Easy Eddies for stress relief, Go Betty Go for an energy boost, Ache Away Eddies for pain relief, Ache Away Eddies PM for a pain-free night's sleep, Betty's Carameltway for cozy melty moments of mellow, and more.Board Change • Jan 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Eva Selhub was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 22MariMed Inc. Launches Hemp-Derived THC Products Under Its Vibations Brand in Rhode IslandMariMed Inc. announced the launch of a hemp-derived THC version of its Vibations™? hydrating drink mix brand in Rhode Island. The launch represents a capital-efficient opportunity for the Company to expand Vibations into the rapidly growing hemp THC beverage category through an established retail channel, without incremental cultivation or retail infrastructure investment. MariMed believes hemp-derived THC beverages provide a scalable pathway to incremental revenue and accretive gross margin, while maintaining disciplined capital deployment. Distributing a hemp-derived version of Vibations also advances MariMed's Expand the Brand strategy, which is focused on broadening distribution of the Company's core brands and achieving a goal of owning top-selling, national cannabis brands. According to BDSA and Lit Alerts, Vibations is a top 10 selling cannabis beverage brand in Illinois, Massachusetts, Maryland, and Delaware. The hemp-derived THC version of Vibations is infused with 5mg of THC per stick. Flavors available for the Rhode Island launch include Lemon Lime (Sugar Free), Half & Half, Strawberry Lemonade, and Tropical Punch. Distribution will be provided through licensed Rhode Island liquor stores that are authorized to carry hemp THC beverages and products, providing an efficient and scalable retail channel for market entry. There are currently more than 150 licensed and approved liquor stores in the state. Distribution of Vibations in Rhode Island is supported by Craft Collective Homegrown, the leading hemp beverage distributor in the state, which will manage weekly ordering and delivery. MariMed has also entered a new partnership with Modern Infusions, the hemp THC beverage division of Theory Wellness, to manage sales execution and local marketing initiatives, including distributor management, account development, retail merchandising, and short and long-term sales planning. The Company is also developing plans to expand distribution of Vibations into additional markets during the first half of 2026. Those plans will be contingent on the early performance of the Rhode Island launch and other regulatory considerations and would be implemented using a similarly disciplined and capital-efficient distribution model.お知らせ • Oct 29Marimed Announces Strategic Exit from Missouri MarketMariMed Inc. announced that it has completed a strategic review of its Missouri business operations and decided to exit the market, effectively immediately. Since 2024, the Company has managed the Missouri operations of another licensed cannabis operator and distributed certain of its brands there under a Managed Services and Licensing Agreement, while awaiting license transfer approval from the state. The Company will no longer manage the facility and will no longer seek the license transfer. MariMed continues to own or manage revenue-generating operations in six states, including 13 dispensaries and six cultivation and processing facilities in Delaware, Illinois, Maryland, Massachusetts, Ohio, and Pennsylvania. Exiting Missouri is expected to improve the Company’s overall financial performance, particularly gross margin and adjusted EBITDA, and allow management to focus resources on higher return opportunities.お知らせ • Sep 29MariMed Inc. to Report Q3, 2025 Results on Nov 05, 2025MariMed Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2025Reported Earnings • Aug 08Second quarter 2025 earnings released: US$0.003 loss per share (vs US$0.004 loss in 2Q 2024)Second quarter 2025 results: US$0.003 loss per share (improved from US$0.004 loss in 2Q 2024). Revenue: US$39.6m (down 2.0% from 2Q 2024). Net loss: US$1.27m (loss narrowed 23% from 2Q 2024). Revenue is forecast to grow 9.8% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.お知らせ • Jul 08MariMed Inc. to Report Q2, 2025 Results on Aug 06, 2025MariMed Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025Board Change • Jun 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Eva Selhub was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 29MariMed's Premium Nature's Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDoseMariMed Inc. continued to drive innovation with the launch of MycroDose by Nature's Heritage, a vegan line of all-natural wellness products that combine the power of full-spectrum cannabis with the added benefits of functional mushrooms in a convenient pill form. MycroDose by Natures Heritage delivers four targeted, plant-based solutions designed to enhance mental clarity, promote relaxation, improve focus, and support overall well-being in four distinct formulations. They are available now in Massachusetts at MariMed's own Panacea Wellness stores and other select dispensaries. The new line was developed to provide new and existing consumers with a unique, balanced, and controlled experience. Each of the four MycroDose by Nature' Heritage products are uniquely crafted with a specific blend of all natural vegan ingredients to cater to a variety of needs. The complete line-up includes: Chill - Designed for relaxation and stress relief, Chill features THC, CBD, and q, blended with the functional mushrooms Organic Cordyceps and Organic Lion's Mane, and the root plant, Ashwagandha. G'Night - A formulation aimed at improved sleep and deep relaxation, G'Night combines THC, CBN, CBD with functional mushrooms Organic Reishi and Organic Lion's Mane, as well as Chamomile and Magnesium. Remedy - A product focused on reducing inflammation while providing a calm state of mind, Remedy features THC, CBD, and CBC, blended with the functional mushroom Oyster, Ginger root, Turmeric, and Piperine. Spark - An energizing blend designed to improve energy, focus, and mental clarity, Spark is formulated with Shoitake mushrooms, Organic Lion's Mane, Ginseng, THCV, and THC.New Risk • May 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$16m Forecast net loss in 1 year: US$1.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (25% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$1.8m net loss next year). Market cap is less than US$100m (CA$51.5m market cap, or US$37.0m).Reported Earnings • May 10First quarter 2025 earnings released: US$0.014 loss per share (vs US$0.003 loss in 1Q 2024)First quarter 2025 results: US$0.014 loss per share (further deteriorated from US$0.003 loss in 1Q 2024). Revenue: US$38.0m (flat on 1Q 2024). Net loss: US$5.45m (loss widened 320% from 1Q 2024). Revenue is forecast to grow 7.6% p.a. on average during the next 2 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in Canada.New Risk • May 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 105% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (105% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$109.2m market cap, or US$79.3m).お知らせ • May 01MariMed Inc., Annual General Meeting, Jun 12, 2025MariMed Inc., Annual General Meeting, Jun 12, 2025. Location: sheraton norwood, 1125 boston providence turnpike, norwood, massachusetts 02062, United Statesお知らせ • Apr 08MariMed Inc. to Report Q1, 2025 Results on May 07, 2025MariMed Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025お知らせ • Apr 07MariMed Inc. Promotes Ryan Crandall to Chief Commercial OfficerMariMed Inc. has promoted Ryan Crandall to Chief Commercial Officer, effective immediately. In his new role, Mr. Crandall will lead the Company’s commercial strategy and activities, including Sales, Marketing, Product Development, and Retail Operations. He has served as MariMed’s Chief Revenue Officer since July 2022, and prior was the Company’s Chief Products Officer and SVP, Sales for four years. Mr. Crandall will continue to report to MariMed CEO Jon Levine. Mr. Crandall entered the cannabis industry in 2014 when he co-created Betty’s Eddies. Prior, he held a series of executive positions with increasing sales responsibilities in major cybersecurity and software corporations, including RSA Security and EMC2.お知らせ • Apr 03MariMed Inc.'s Betty's Eddies Expands Top-Selling Brand with Introduction of THC & CBG-Infused Caramel ChewsBetty's Eddies is expanding its lineup with the introduction of delicious caramel chews: Betty's Caramelt Away. Betty's Eddies is one of the top-selling and award-winning brands developed and distributed by leading multi-state cannabis operator, MariMed Inc. Deuting in time for National Caramel Day on April 5, Betty's Caramelt Away chews are now available at select cannabis retailers throughout Massachusetts, with plans for expansion into MariMed's wholesale markets in the future. Each chew wraps customers in warmth with the rich, comforting flavor of classic caramel. They're infused with a soothing blend of full-spectrum hash and CBG that lets consumers sink into sweet, cozy melty moments of mellow. Betty's Caramelt Away joins a full slate of Betty's Eddies products that feature specific end-effects, including Bedtime Betty's for restful nights, Take It Easy Eddies for stress relief, Go Betty Go for an energy boost, Ache Away Eddies for pain relief, Smashin' Passion for sexual wellness, and Betty Good Times for any time.お知らせ • Apr 02Marimed Launches Nature's Heritage Flower in IllinoisMariMed Inc. has officially introduced its Nature's Heritage™?-branded cannabis flower, pre-rolls, and vapes in Illinois. This marks the first time the brand's premium products are available in the state. The launch follows the late 2024 openning of MariMed's Mt. Vernon, Illinois, cultivation facility. Nature's Heritage products are available at MariMed's five -branded dispensaries and other select retailers in the state. Thrive-branded dispensaries and other select retailer in the state. The entire portfolio of MariMed's award-winning brands is now available in the state. The Company's processing facility commenced distribution of its other products, including Betty's Eddies™?, Bubby's Baked™?, InHouse™?, and Vibations™? products, in late 2023. Since then, MariMed has successfully penetrated the market, with its products currently available in approximately 82% of Illinois dispensaries.Reported Earnings • Mar 07Full year 2024 earnings released: US$0.032 loss per share (vs US$0.044 loss in FY 2023)Full year 2024 results: US$0.032 loss per share (improved from US$0.044 loss in FY 2023). Revenue: US$158.0m (up 6.3% from FY 2023). Net loss: US$12.2m (loss narrowed 24% from FY 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 2 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Mar 05MariMed Inc. (OTCPK:MRMD) completed the acquisition of First State Compassion Center Inc.MariMed Inc. (OTCPK:MRMD) entered into an agreement to acquire First State Compassion Center Inc. on July 1, 2023. MariMed Inc. (OTCPK:MRMD) completed the acquisition of First State Compassion Center Inc. on March 3, 2025.お知らせ • Feb 11MariMed Inc. to Report Q4, 2024 Results on Mar 05, 2025MariMed Inc. announced that they will report Q4, 2024 results After-Market on Mar 05, 2025Reported Earnings • Nov 09Third quarter 2024 earnings released: US$0.003 loss per share (vs US$0.011 loss in 3Q 2023)Third quarter 2024 results: US$0.003 loss per share (improved from US$0.011 loss in 3Q 2023). Revenue: US$40.6m (up 4.6% from 3Q 2023). Net loss: US$1.01m (loss narrowed 76% from 3Q 2023).お知らせ • Oct 07MariMed Inc. to Report Q3, 2024 Results on Nov 06, 2024MariMed Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024Reported Earnings • Aug 08Second quarter 2024 earnings released: US$0.004 loss per share (vs US$0.003 loss in 2Q 2023)Second quarter 2024 results: US$0.004 loss per share (further deteriorated from US$0.003 loss in 2Q 2023). Revenue: US$40.4m (up 11% from 2Q 2023). Net loss: US$1.65m (loss widened 72% from 2Q 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Aug 08+ 1 more updateMarimed Inc. Reaffirms Earnings Guidance for the Full Year 2024MariMed Inc. reaffirmed earnings guidance for the full year 2024. MariMed's full year 2024 financial targets are based on organic growth of its existing operating assets and do not include new revenue-generating projects requiring regulatory approvals. As such, the Company's full year 2024 financial targets remain at: Revenue growth of 5% to 7%.お知らせ • Jul 10MariMed Inc. to Report Q2, 2024 Results on Aug 07, 2024MariMed Inc. announced that they will report Q2, 2024 results on Aug 07, 2024お知らせ • Jul 02MariMed Inc. Announces Approval of Adult-Use Sales at Panacea Wellness Dispensary in Quincy, Massachusetts and Updates for Ohio and MarylandMariMed Inc. announced that it received approval of the Massachusetts Cannabis Control Commission ("MCCC") to commence adult-use retail sales at its QuincyPanacea Wellness dispensary. Panacea WellnessQuincy is the third MariMed dispensary in Massachusetts that offers adult-use sales, which is the maximum permissible by state law. The other two adult-use dispensaries are in Leverly and Middleboro. The Company commenced adult-use sales in Quincy on July 2, 2024. The dispensary, which has been operating as a medical-only location, offers a curated selection of products from across the Company's award-winning brand portfolio. They include Nature's Heritage flower and concentrates, Betty's Eddies fruit chews, Bubby's Baked soft-baked goods, Vibations hydrating cannabis drink mixes, and the full suite of InHouse branded products. In addition to the three Panacea Wellness locations, MariMed's branded cannabis products are distributed to over 200 dispensaries in the Massachusetts cannabis market, which, according to the MCCC, generated $1.8 billion in total cannabis sales during 2023. The Company also announced regulatory approval updates that may have a positive impact on future operational and financial results. These include: Ohio: Receipt of a provisional dual-use license to add recreational sales to medical dispensary in Tiffin. Upon state final inspection, MariMed expects to commence adult-use sales. Maryland: Receipt of a Certificate of Occupancy and state approval to commence operations in the newly expanded area of cultivation facility in Hagerstown, Maryland. MariMed will begin growing in the new flower rooms immediately to meet the high demand for its Nature's Heritage flower and other branded products in that state. Also in Maryland, the pre-occupancy inspection of second Thrive dispensary in the state is expected to occur. The Company hopes to commence adult-use operations in this dispensary, located in Upper Marlboro, a town in Prince George's County, later this month.お知らせ • May 10MariMed Inc. Provides Earning Guidance for the Full Year 2024MariMed Inc. provided earning guidance for the full year 2024. For the year, the company's financial targets remain at: revenue growth of 5% to 7%.Reported Earnings • May 09First quarter 2024 earnings released: US$0.003 loss per share (vs US$0.002 loss in 1Q 2023)First quarter 2024 results: US$0.003 loss per share (further deteriorated from US$0.002 loss in 1Q 2023). Revenue: US$37.9m (up 10% from 1Q 2023). Net loss: US$1.30m (loss widened 101% from 1Q 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 2 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Apr 10MariMed Inc. (OTCPK:MRMD) completed the acquisition of Operating assets of Our Community Wellness & Compassionate Care Center, Inc for $5.3 million.MariMed Inc. (OTCPK:MRMD) entered into a definitive agreement to acquire Operating assets of Our Community Wellness & Compassionate Care Center, Inc. for $5.3 million on February 1, 2024. The purchase consideration is comprised of $2 million of cash in the aggregate, a $2 million note to be issued to the sellers at the time of closing, and shares of MariMed's common stock with a fair value of $1.25 million based on a formulaic calculation, to be issued at the time of closing. Transaction is subject to approval by the Maryland Cannabis Administration. MariMed expects this acquisition to be completed in 2024. MariMed Inc. (OTCPK:MRMD) completed the acquisition of Operating assets of Our Community Wellness & Compassionate Care Center, Inc on April 9, 2024.お知らせ • Apr 09MariMed Inc. to Report Q1, 2024 Results on May 08, 2024MariMed Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024お知らせ • Mar 20MariMed Inc., Annual General Meeting, Jun 06, 2024MariMed Inc., Annual General Meeting, Jun 06, 2024.New Risk • Mar 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (CA$116.4m market cap, or US$85.9m).お知らせ • Mar 08MariMed Inc. (OTCPK:MRMD) entered into a definitive agreement to acquire Operating assets of Our Community Wellness & Compassionate Care Center, Inc. for $5.3 million.MariMed Inc. (OTCPK:MRMD) entered into a definitive agreement to acquire Operating assets of Our Community Wellness & Compassionate Care Center, Inc. for $5.3 million on February 1, 2024. The purchase consideration is comprised of $2 million of cash in the aggregate, a $2 million note to be issued to the sellers at the time of closing, and shares of MariMed's common stock with a fair value of $1.25 million based on a formulaic calculation, to be issued at the time of closing. Transaction is subject to approval by the Maryland Cannabis Administration. MariMed expects this acquisition to be completed in 2024.Reported Earnings • Mar 08Full year 2023 earnings released: US$0.044 loss per share (vs US$0.04 profit in FY 2022)Full year 2023 results: US$0.044 loss per share (down from US$0.04 profit in FY 2022). Revenue: US$148.6m (up 11% from FY 2022). Net loss: US$16.0m (down 219% from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 9.7% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Mar 07MariMed Inc. Provides Earnings Guidance for the Full Year 2024MariMed Inc. provided earning guidance for the full year 2024. For the year, the company expects revenue growth of 5% to 7%.New Risk • Mar 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: CA$134.1m (US$98.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (CA$134.1m market cap, or US$98.8m).お知らせ • Feb 06MariMed Inc. to Report Q4, 2023 Results on Mar 06, 2024MariMed Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Mar 06, 2024お知らせ • Dec 04MariMed Inc. Commences Operations of Processing Facility in Mt. Vernon, IllinoisMariMed Inc. announced it has begun manufacturing and processing cannabis products in its new processing kitchen in Mt. Vernon, Illinois. After lengthy construction and regulatory delays, the Company expects that its award-winning products will be available at dispensaries in Illinois in time for the holidays. These include MariMed's five Thrive Dispensary-branded retail locations in the state. The processing facility contains an extraction lab to produce concentrates, and a production kitchen for the manufacture of edibles and other derivative products. The cultivation facility is currently under construction in the same facility and is expected to be completed in 2024. MariMed intends to manufacture and distribute its proprietary brands and products throughout Illinois. That includes its Betty's Eddies fruit chews, which was the top-selling edible in Illinois until 2020 through a third-party licensing agreement, Bubby's Baked soft and chewy baked edibles, Vibations hydrating drink mix, InHouse gummies, K Fusion chewable tablets, and more. Upon completion of the cultivation facility construction the Company plans to commence selling its Nature's Heritage flower through retail and wholesale channels. MariMed operates five Thrive Dispensary locations in Anna, Casey, Harrisburg, Metropolis, and Mt. Vernon, Illinois.Reported Earnings • Nov 10Third quarter 2023 earnings released: US$0.011 loss per share (vs US$0.008 profit in 3Q 2022)Third quarter 2023 results: US$0.011 loss per share (down from US$0.008 profit in 3Q 2022). Revenue: US$38.8m (up 14% from 3Q 2022). Net loss: US$4.26m (down 257% from profit in 3Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Nov 05MariMed Inc. Announces Executive ChangesMariMed Inc. announced that effective October 31, 2023, Susan M. Villare resigned as Chief Financial Officer of the Company. The Board of Directors has appointed Jon Levine, President and CEO, as the Company’s Interim Chief Financial Officer and has initiated a search process to identify and engage a new Chief Financial Officer.お知らせ • Nov 04MariMed Inc. to Report Q3, 2023 Results on Nov 08, 2023MariMed Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023お知らせ • Sep 14MariMed Inc. Announces its Bubby's Baked Introduces New THC-Infused Blueberry Muffin Bites to Start Day on High NoteMariMed Inc. headed to the blueberry bush to create the latest addition to its Bubby’s Baked™ THC-infused soft baked goods line of edibles. The Company’s new Blueberry Muffin bites are soft and baked in small batches, a made-from-scratch ode to breakfast. They join the popular Bubby’s Baked line inspired by the original pot brownie recipe and are available at select dispensaries in Massachusetts, Maryland, and Delaware. Each Bubby’s Baked Blueberry Muffin bite is an enticing combination of sweetness and tartness, bursting with real blueberries and infused with full-spectrum cannabis. With 35% of cannabis consumers saying they have recently enjoyed a cannabis baked good, Bubby’s Baked Blueberry Muffin bites are sure to satisfy the most discerning sweet tooth. In Massachusetts, they are precision-dosed with 5 mg of cannabis; in Maryland and Delaware, they are available with 10 mg of cannabis. The new Blueberry Muffin bites join the other three flavors in the Bubby’s Baked line-up, including classic Brownie, Choco Chip and Snickerdoodle. The Bubby’s Baked brand was inspired by the original homemade pot brownie. The brand’s classic Brownie flavor was intended to recreate and elevate the nostalgic experience so many consumers remember as their first cannabis-infused edible. Other flavors in the line include Choco Chip and Snickerdoodle.Reported Earnings • Aug 04Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.005 profit in 2Q 2022)Second quarter 2023 results: US$0.003 loss per share (down from US$0.005 profit in 2Q 2022). Revenue: US$36.5m (up 11% from 2Q 2022). Net loss: US$958.0k (down 153% from profit in 2Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Jun 30MariMed Inc. to Report Q2, 2023 Results on Aug 02, 2023MariMed Inc. announced that they will report Q2, 2023 results After-Market on Aug 02, 2023Reported Earnings • May 10First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.013 profit in 1Q 2022)First quarter 2023 results: US$0.002 loss per share (down from US$0.013 profit in 1Q 2022). Revenue: US$34.4m (up 9.9% from 1Q 2022). Net loss: US$645.0k (down 115% from profit in 1Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • May 09MariMed Inc. Provides Revenue Guidance for the Full Year 2023MariMed Inc. provided revenue guidance for the full year 2023. For the period, the company expects revenue of at least $150 million.Board Change • Mar 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Eva Selhub was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 04Full year 2022 earnings released: EPS: US$0.04 (vs US$0.022 in FY 2021)Full year 2022 results: EPS: US$0.04 (up from US$0.022 in FY 2021). Revenue: US$134.0m (up 10% from FY 2021). Net income: US$13.5m (up 86% from FY 2021). Profit margin: 10.0% (up from 5.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Feb 02MariMed Inc. to Report Q4, 2022 Results on Mar 01, 2023MariMed Inc. announced that they will report Q4, 2022 results After-Market on Mar 01, 2023Board Change • Jan 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Eva Selhub was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Dec 15MariMed Inc. Appoints Jon Levine as Interim Chief Executive OfficerMariMed Inc. announced its Board of Directors appointed Jon Levine, MariMed’s President, as Interim Chief Executive Officer. The Board will conduct a process to identify a permanent Chief Executive Officer for MariMed, which may include external and internal candidates. The Company will announce an update on the process upon completion. No timing was provided for the duration of the process.お知らせ • Dec 13+ 1 more updateMarimed, Inc. Announces Death of Chairman Robert FiremanMariMed Inc. announced with deep sadness that Chairman and co-founder Robert Fireman died unexpectedly on December 11, 2022.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Eva Selhub was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Nov 08MariMed Inc. Provides Earnings Guidance for Full Year 2022MariMed Inc. provided earnings guidance for full year 2022. For the year, the company expects Revenue of $132 million to $135 million.お知らせ • Oct 13MariMed Inc. to Report Q3, 2022 Results on Nov 07, 2022MariMed Inc. announced that they will report Q3, 2022 results After-Market on Nov 07, 2022Board Change • Oct 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Eva Selhub was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Sep 23MariMed Inc., Annual General Meeting, Oct 27, 2022MariMed Inc., Annual General Meeting, Oct 27, 2022, at 10:00 Eastern Daylight. Location: Hilton Boston/Dedham Hotel located at 25 Allied Drive Dedham, Massachusetts 02026 Dedham Massachusetts United States Agenda: To consider and approve the election of five Directors to serve until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified; to consider and approve the advisory approval of the appointment of M&K CPAs PLLC as the Company’s independent auditors for the fiscal year ending December 31, 2022; and to consider other matters.お知らせ • Sep 08+ 2 more updatesMariMed, Inc. Announces the Availability of A New and Scrumptious Cannabis-Infused Ice CreamMariMed Inc. announced the availability of a new and scrumptious cannabis-infused ice cream. MariMed collaborated with the legendary Boston ice cream brand Emack & Bolio's® to develop and market new and innovative vegan and dairy ice cream in outrageous flavors. The ice cream is an extension of MariMed's top-selling and award-winning Betty's Eddies infused fruit chews brand and shares the brand's commitment to being hand-crafted and using all-natural ingredients. The ice cream contains MariMed's superior formulations of full spectrum cannabis oil, with natural cannabinoids and terpenes. Two delicious vegan flavors, Cup O' Coffee Chip and Chocolate Sunny Days, debuted at MariMed's Panacea Wellness dispensary in Middleborough, MA, this week. Additional flavors and wider availability are expected in the coming months.Reported Earnings • Aug 10Second quarter 2022 earnings released: EPS: US$0.005 (vs US$0.023 in 2Q 2021)Second quarter 2022 results: EPS: US$0.005 (down from US$0.023 in 2Q 2021). Revenue: US$33.0m (up 1.3% from 2Q 2021). Net income: US$1.82m (down 76% from 2Q 2021). Profit margin: 5.5% (down from 23% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 14%, compared to a 66% growth forecast for the industry in Canada.お知らせ • Aug 09MariMed Inc. Revises Earnings Guidance for 2022MariMed Inc. revised earnings guidance for 2022. For the period, the company now expects Revenue in the range of $135 million to $140 million versus the previous range of $145 million to $150 million.収支内訳MariMed の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史CNSX:MRMD 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 26161-1359031 Dec 25160-1460030 Sep 25157-1859030 Jun 25157-1660031 Mar 25158-1661031 Dec 24158-1259030 Sep 24158-1460030 Jun 24156-1758031 Mar 24152-1755031 Dec 23149-1651030 Sep 23146-149030 Jun 23141645031 Mar 23137943031 Dec 221341343030 Sep 22129244030 Jun 22129246031 Mar 22128743031 Dec 21121739030 Sep 211111829030 Jun 21911722031 Mar 2168919031 Dec 2051217030 Sep 2036-8050030 Jun 2033-8948031 Mar 2050-8448031 Dec 1946-8146030 Sep 1944-1016030 Jun 1936-715031 Mar 1913-1213031 Dec 1812-1412030 Sep 1810-77030 Jun 188-46031 Mar 187-35031 Dec 176-14030 Sep 17603030 Jun 17502031 Mar 17402031 Dec 164010質の高い収益: MRMDは現在利益が出ていません。利益率の向上: MRMDは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MRMDは利益が出ておらず、過去 5 年間で損失は年間61.9%の割合で増加しています。成長の加速: MRMDの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: MRMDは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 64.6% ) と比較することは困難です。株主資本利益率高いROE: MRMDは現在利益が出ていないため、自己資本利益率 ( -23.84% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 10:04終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MariMed Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Joseph GomesNOBLE Capital Markets, Inc.Andrew SempleVentum Financial CorpPablo ZuanicZuanic & Associates
Reported Earnings • May 14First quarter 2026 earnings released: US$0.01 loss per share (vs US$0.014 loss in 1Q 2025)First quarter 2026 results: US$0.01 loss per share (improved from US$0.014 loss in 1Q 2025). Revenue: US$39.5m (up 4.0% from 1Q 2025). Net loss: US$3.79m (loss narrowed 31% from 1Q 2025). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 42% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 16MariMed Inc. to Report Q1, 2026 Results on May 13, 2026MariMed Inc. announced that they will report Q1, 2026 results After-Market on May 13, 2026
Reported Earnings • Mar 13Full year 2025 earnings released: US$0.037 loss per share (vs US$0.032 loss in FY 2024)Full year 2025 results: US$0.037 loss per share (further deteriorated from US$0.032 loss in FY 2024). Revenue: US$159.8m (up 1.2% from FY 2024). Net loss: US$14.5m (loss widened 19% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 11MariMed Inc. to Report Q4, 2025 Results on Mar 11, 2026MariMed Inc. announced that they will report Q4, 2025 results After-Market on Mar 11, 2026
お知らせ • Sep 29MariMed Inc. to Report Q3, 2025 Results on Nov 05, 2025MariMed Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2025
Reported Earnings • Aug 08Second quarter 2025 earnings released: US$0.003 loss per share (vs US$0.004 loss in 2Q 2024)Second quarter 2025 results: US$0.003 loss per share (improved from US$0.004 loss in 2Q 2024). Revenue: US$39.6m (down 2.0% from 2Q 2024). Net loss: US$1.27m (loss narrowed 23% from 2Q 2024). Revenue is forecast to grow 9.8% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 14First quarter 2026 earnings released: US$0.01 loss per share (vs US$0.014 loss in 1Q 2025)First quarter 2026 results: US$0.01 loss per share (improved from US$0.014 loss in 1Q 2025). Revenue: US$39.5m (up 4.0% from 1Q 2025). Net loss: US$3.79m (loss narrowed 31% from 1Q 2025). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 42% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 25MariMed Inc., Annual General Meeting, Jun 04, 2026MariMed Inc., Annual General Meeting, Jun 04, 2026.
お知らせ • Apr 16MariMed Inc. to Report Q1, 2026 Results on May 13, 2026MariMed Inc. announced that they will report Q1, 2026 results After-Market on May 13, 2026
Buy Or Sell Opportunity • Apr 06Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 35% to CA$0.085. The fair value is estimated to be CA$0.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.6% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 7.8% per annum. Earnings are also forecast to grow by 19% per annum over the same time period.
Reported Earnings • Mar 13Full year 2025 earnings released: US$0.037 loss per share (vs US$0.032 loss in FY 2024)Full year 2025 results: US$0.037 loss per share (further deteriorated from US$0.032 loss in FY 2024). Revenue: US$159.8m (up 1.2% from FY 2024). Net loss: US$14.5m (loss widened 19% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 11MariMed Inc. to Report Q4, 2025 Results on Mar 11, 2026MariMed Inc. announced that they will report Q4, 2025 results After-Market on Mar 11, 2026
お知らせ • Feb 06MariMed's Eddies Introduces New Limited-Edition Valentine's Seasonal, Berry in Love BettyBetty's Eddies is expanding its lineup with a new limited-edition batch of strawberry chocolate chews in time for Valentine's Day: Berry In Love Betty. Betty's Eddies is one of the top-selling and award-winning brands developed and distributed by leading multi-state cannabis operator, MariMed Inc. Now available at MariMed's Thrive Dispensary locations and other cannabis retailers throughout Massachusetts, Maryland, Illinois, and Delaware, each libido-enhancing Berry In Love Bettychew is infused with full-spectrum cannabis, CBG, and horny goat weed, an herb used in China that may help increase blood flow and sexual function. All Betty's Eddie chews are vegan, gluten-free, and dairy-free. Berry In Love Betty chews stand out as the brand's first swirled chew, combining an eye-catching presentation with all-natural ingredients made from organic fruits and chocolate. Berry In Love Betty joins a full slate of Betty's Eddies products that feature specific end-effects, including Bedtime Betty's for restful nights, Take It Easy Eddies for stress relief, Go Betty Go for an energy boost, Ache Away Eddies for pain relief, Ache Away Eddies PM for a pain-free night's sleep, Betty's Carameltway for cozy melty moments of mellow, and more.
Board Change • Jan 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Eva Selhub was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 22MariMed Inc. Launches Hemp-Derived THC Products Under Its Vibations Brand in Rhode IslandMariMed Inc. announced the launch of a hemp-derived THC version of its Vibations™? hydrating drink mix brand in Rhode Island. The launch represents a capital-efficient opportunity for the Company to expand Vibations into the rapidly growing hemp THC beverage category through an established retail channel, without incremental cultivation or retail infrastructure investment. MariMed believes hemp-derived THC beverages provide a scalable pathway to incremental revenue and accretive gross margin, while maintaining disciplined capital deployment. Distributing a hemp-derived version of Vibations also advances MariMed's Expand the Brand strategy, which is focused on broadening distribution of the Company's core brands and achieving a goal of owning top-selling, national cannabis brands. According to BDSA and Lit Alerts, Vibations is a top 10 selling cannabis beverage brand in Illinois, Massachusetts, Maryland, and Delaware. The hemp-derived THC version of Vibations is infused with 5mg of THC per stick. Flavors available for the Rhode Island launch include Lemon Lime (Sugar Free), Half & Half, Strawberry Lemonade, and Tropical Punch. Distribution will be provided through licensed Rhode Island liquor stores that are authorized to carry hemp THC beverages and products, providing an efficient and scalable retail channel for market entry. There are currently more than 150 licensed and approved liquor stores in the state. Distribution of Vibations in Rhode Island is supported by Craft Collective Homegrown, the leading hemp beverage distributor in the state, which will manage weekly ordering and delivery. MariMed has also entered a new partnership with Modern Infusions, the hemp THC beverage division of Theory Wellness, to manage sales execution and local marketing initiatives, including distributor management, account development, retail merchandising, and short and long-term sales planning. The Company is also developing plans to expand distribution of Vibations into additional markets during the first half of 2026. Those plans will be contingent on the early performance of the Rhode Island launch and other regulatory considerations and would be implemented using a similarly disciplined and capital-efficient distribution model.
お知らせ • Oct 29Marimed Announces Strategic Exit from Missouri MarketMariMed Inc. announced that it has completed a strategic review of its Missouri business operations and decided to exit the market, effectively immediately. Since 2024, the Company has managed the Missouri operations of another licensed cannabis operator and distributed certain of its brands there under a Managed Services and Licensing Agreement, while awaiting license transfer approval from the state. The Company will no longer manage the facility and will no longer seek the license transfer. MariMed continues to own or manage revenue-generating operations in six states, including 13 dispensaries and six cultivation and processing facilities in Delaware, Illinois, Maryland, Massachusetts, Ohio, and Pennsylvania. Exiting Missouri is expected to improve the Company’s overall financial performance, particularly gross margin and adjusted EBITDA, and allow management to focus resources on higher return opportunities.
お知らせ • Sep 29MariMed Inc. to Report Q3, 2025 Results on Nov 05, 2025MariMed Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2025
Reported Earnings • Aug 08Second quarter 2025 earnings released: US$0.003 loss per share (vs US$0.004 loss in 2Q 2024)Second quarter 2025 results: US$0.003 loss per share (improved from US$0.004 loss in 2Q 2024). Revenue: US$39.6m (down 2.0% from 2Q 2024). Net loss: US$1.27m (loss narrowed 23% from 2Q 2024). Revenue is forecast to grow 9.8% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 08MariMed Inc. to Report Q2, 2025 Results on Aug 06, 2025MariMed Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025
Board Change • Jun 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Eva Selhub was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 29MariMed's Premium Nature's Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDoseMariMed Inc. continued to drive innovation with the launch of MycroDose by Nature's Heritage, a vegan line of all-natural wellness products that combine the power of full-spectrum cannabis with the added benefits of functional mushrooms in a convenient pill form. MycroDose by Natures Heritage delivers four targeted, plant-based solutions designed to enhance mental clarity, promote relaxation, improve focus, and support overall well-being in four distinct formulations. They are available now in Massachusetts at MariMed's own Panacea Wellness stores and other select dispensaries. The new line was developed to provide new and existing consumers with a unique, balanced, and controlled experience. Each of the four MycroDose by Nature' Heritage products are uniquely crafted with a specific blend of all natural vegan ingredients to cater to a variety of needs. The complete line-up includes: Chill - Designed for relaxation and stress relief, Chill features THC, CBD, and q, blended with the functional mushrooms Organic Cordyceps and Organic Lion's Mane, and the root plant, Ashwagandha. G'Night - A formulation aimed at improved sleep and deep relaxation, G'Night combines THC, CBN, CBD with functional mushrooms Organic Reishi and Organic Lion's Mane, as well as Chamomile and Magnesium. Remedy - A product focused on reducing inflammation while providing a calm state of mind, Remedy features THC, CBD, and CBC, blended with the functional mushroom Oyster, Ginger root, Turmeric, and Piperine. Spark - An energizing blend designed to improve energy, focus, and mental clarity, Spark is formulated with Shoitake mushrooms, Organic Lion's Mane, Ginseng, THCV, and THC.
New Risk • May 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$16m Forecast net loss in 1 year: US$1.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (25% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$1.8m net loss next year). Market cap is less than US$100m (CA$51.5m market cap, or US$37.0m).
Reported Earnings • May 10First quarter 2025 earnings released: US$0.014 loss per share (vs US$0.003 loss in 1Q 2024)First quarter 2025 results: US$0.014 loss per share (further deteriorated from US$0.003 loss in 1Q 2024). Revenue: US$38.0m (flat on 1Q 2024). Net loss: US$5.45m (loss widened 320% from 1Q 2024). Revenue is forecast to grow 7.6% p.a. on average during the next 2 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in Canada.
New Risk • May 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 105% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (105% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$109.2m market cap, or US$79.3m).
お知らせ • May 01MariMed Inc., Annual General Meeting, Jun 12, 2025MariMed Inc., Annual General Meeting, Jun 12, 2025. Location: sheraton norwood, 1125 boston providence turnpike, norwood, massachusetts 02062, United States
お知らせ • Apr 08MariMed Inc. to Report Q1, 2025 Results on May 07, 2025MariMed Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025
お知らせ • Apr 07MariMed Inc. Promotes Ryan Crandall to Chief Commercial OfficerMariMed Inc. has promoted Ryan Crandall to Chief Commercial Officer, effective immediately. In his new role, Mr. Crandall will lead the Company’s commercial strategy and activities, including Sales, Marketing, Product Development, and Retail Operations. He has served as MariMed’s Chief Revenue Officer since July 2022, and prior was the Company’s Chief Products Officer and SVP, Sales for four years. Mr. Crandall will continue to report to MariMed CEO Jon Levine. Mr. Crandall entered the cannabis industry in 2014 when he co-created Betty’s Eddies. Prior, he held a series of executive positions with increasing sales responsibilities in major cybersecurity and software corporations, including RSA Security and EMC2.
お知らせ • Apr 03MariMed Inc.'s Betty's Eddies Expands Top-Selling Brand with Introduction of THC & CBG-Infused Caramel ChewsBetty's Eddies is expanding its lineup with the introduction of delicious caramel chews: Betty's Caramelt Away. Betty's Eddies is one of the top-selling and award-winning brands developed and distributed by leading multi-state cannabis operator, MariMed Inc. Deuting in time for National Caramel Day on April 5, Betty's Caramelt Away chews are now available at select cannabis retailers throughout Massachusetts, with plans for expansion into MariMed's wholesale markets in the future. Each chew wraps customers in warmth with the rich, comforting flavor of classic caramel. They're infused with a soothing blend of full-spectrum hash and CBG that lets consumers sink into sweet, cozy melty moments of mellow. Betty's Caramelt Away joins a full slate of Betty's Eddies products that feature specific end-effects, including Bedtime Betty's for restful nights, Take It Easy Eddies for stress relief, Go Betty Go for an energy boost, Ache Away Eddies for pain relief, Smashin' Passion for sexual wellness, and Betty Good Times for any time.
お知らせ • Apr 02Marimed Launches Nature's Heritage Flower in IllinoisMariMed Inc. has officially introduced its Nature's Heritage™?-branded cannabis flower, pre-rolls, and vapes in Illinois. This marks the first time the brand's premium products are available in the state. The launch follows the late 2024 openning of MariMed's Mt. Vernon, Illinois, cultivation facility. Nature's Heritage products are available at MariMed's five -branded dispensaries and other select retailers in the state. Thrive-branded dispensaries and other select retailer in the state. The entire portfolio of MariMed's award-winning brands is now available in the state. The Company's processing facility commenced distribution of its other products, including Betty's Eddies™?, Bubby's Baked™?, InHouse™?, and Vibations™? products, in late 2023. Since then, MariMed has successfully penetrated the market, with its products currently available in approximately 82% of Illinois dispensaries.
Reported Earnings • Mar 07Full year 2024 earnings released: US$0.032 loss per share (vs US$0.044 loss in FY 2023)Full year 2024 results: US$0.032 loss per share (improved from US$0.044 loss in FY 2023). Revenue: US$158.0m (up 6.3% from FY 2023). Net loss: US$12.2m (loss narrowed 24% from FY 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 2 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Mar 05MariMed Inc. (OTCPK:MRMD) completed the acquisition of First State Compassion Center Inc.MariMed Inc. (OTCPK:MRMD) entered into an agreement to acquire First State Compassion Center Inc. on July 1, 2023. MariMed Inc. (OTCPK:MRMD) completed the acquisition of First State Compassion Center Inc. on March 3, 2025.
お知らせ • Feb 11MariMed Inc. to Report Q4, 2024 Results on Mar 05, 2025MariMed Inc. announced that they will report Q4, 2024 results After-Market on Mar 05, 2025
Reported Earnings • Nov 09Third quarter 2024 earnings released: US$0.003 loss per share (vs US$0.011 loss in 3Q 2023)Third quarter 2024 results: US$0.003 loss per share (improved from US$0.011 loss in 3Q 2023). Revenue: US$40.6m (up 4.6% from 3Q 2023). Net loss: US$1.01m (loss narrowed 76% from 3Q 2023).
お知らせ • Oct 07MariMed Inc. to Report Q3, 2024 Results on Nov 06, 2024MariMed Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024
Reported Earnings • Aug 08Second quarter 2024 earnings released: US$0.004 loss per share (vs US$0.003 loss in 2Q 2023)Second quarter 2024 results: US$0.004 loss per share (further deteriorated from US$0.003 loss in 2Q 2023). Revenue: US$40.4m (up 11% from 2Q 2023). Net loss: US$1.65m (loss widened 72% from 2Q 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Aug 08+ 1 more updateMarimed Inc. Reaffirms Earnings Guidance for the Full Year 2024MariMed Inc. reaffirmed earnings guidance for the full year 2024. MariMed's full year 2024 financial targets are based on organic growth of its existing operating assets and do not include new revenue-generating projects requiring regulatory approvals. As such, the Company's full year 2024 financial targets remain at: Revenue growth of 5% to 7%.
お知らせ • Jul 10MariMed Inc. to Report Q2, 2024 Results on Aug 07, 2024MariMed Inc. announced that they will report Q2, 2024 results on Aug 07, 2024
お知らせ • Jul 02MariMed Inc. Announces Approval of Adult-Use Sales at Panacea Wellness Dispensary in Quincy, Massachusetts and Updates for Ohio and MarylandMariMed Inc. announced that it received approval of the Massachusetts Cannabis Control Commission ("MCCC") to commence adult-use retail sales at its QuincyPanacea Wellness dispensary. Panacea WellnessQuincy is the third MariMed dispensary in Massachusetts that offers adult-use sales, which is the maximum permissible by state law. The other two adult-use dispensaries are in Leverly and Middleboro. The Company commenced adult-use sales in Quincy on July 2, 2024. The dispensary, which has been operating as a medical-only location, offers a curated selection of products from across the Company's award-winning brand portfolio. They include Nature's Heritage flower and concentrates, Betty's Eddies fruit chews, Bubby's Baked soft-baked goods, Vibations hydrating cannabis drink mixes, and the full suite of InHouse branded products. In addition to the three Panacea Wellness locations, MariMed's branded cannabis products are distributed to over 200 dispensaries in the Massachusetts cannabis market, which, according to the MCCC, generated $1.8 billion in total cannabis sales during 2023. The Company also announced regulatory approval updates that may have a positive impact on future operational and financial results. These include: Ohio: Receipt of a provisional dual-use license to add recreational sales to medical dispensary in Tiffin. Upon state final inspection, MariMed expects to commence adult-use sales. Maryland: Receipt of a Certificate of Occupancy and state approval to commence operations in the newly expanded area of cultivation facility in Hagerstown, Maryland. MariMed will begin growing in the new flower rooms immediately to meet the high demand for its Nature's Heritage flower and other branded products in that state. Also in Maryland, the pre-occupancy inspection of second Thrive dispensary in the state is expected to occur. The Company hopes to commence adult-use operations in this dispensary, located in Upper Marlboro, a town in Prince George's County, later this month.
お知らせ • May 10MariMed Inc. Provides Earning Guidance for the Full Year 2024MariMed Inc. provided earning guidance for the full year 2024. For the year, the company's financial targets remain at: revenue growth of 5% to 7%.
Reported Earnings • May 09First quarter 2024 earnings released: US$0.003 loss per share (vs US$0.002 loss in 1Q 2023)First quarter 2024 results: US$0.003 loss per share (further deteriorated from US$0.002 loss in 1Q 2023). Revenue: US$37.9m (up 10% from 1Q 2023). Net loss: US$1.30m (loss widened 101% from 1Q 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 2 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Apr 10MariMed Inc. (OTCPK:MRMD) completed the acquisition of Operating assets of Our Community Wellness & Compassionate Care Center, Inc for $5.3 million.MariMed Inc. (OTCPK:MRMD) entered into a definitive agreement to acquire Operating assets of Our Community Wellness & Compassionate Care Center, Inc. for $5.3 million on February 1, 2024. The purchase consideration is comprised of $2 million of cash in the aggregate, a $2 million note to be issued to the sellers at the time of closing, and shares of MariMed's common stock with a fair value of $1.25 million based on a formulaic calculation, to be issued at the time of closing. Transaction is subject to approval by the Maryland Cannabis Administration. MariMed expects this acquisition to be completed in 2024. MariMed Inc. (OTCPK:MRMD) completed the acquisition of Operating assets of Our Community Wellness & Compassionate Care Center, Inc on April 9, 2024.
お知らせ • Apr 09MariMed Inc. to Report Q1, 2024 Results on May 08, 2024MariMed Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024
お知らせ • Mar 20MariMed Inc., Annual General Meeting, Jun 06, 2024MariMed Inc., Annual General Meeting, Jun 06, 2024.
New Risk • Mar 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (CA$116.4m market cap, or US$85.9m).
お知らせ • Mar 08MariMed Inc. (OTCPK:MRMD) entered into a definitive agreement to acquire Operating assets of Our Community Wellness & Compassionate Care Center, Inc. for $5.3 million.MariMed Inc. (OTCPK:MRMD) entered into a definitive agreement to acquire Operating assets of Our Community Wellness & Compassionate Care Center, Inc. for $5.3 million on February 1, 2024. The purchase consideration is comprised of $2 million of cash in the aggregate, a $2 million note to be issued to the sellers at the time of closing, and shares of MariMed's common stock with a fair value of $1.25 million based on a formulaic calculation, to be issued at the time of closing. Transaction is subject to approval by the Maryland Cannabis Administration. MariMed expects this acquisition to be completed in 2024.
Reported Earnings • Mar 08Full year 2023 earnings released: US$0.044 loss per share (vs US$0.04 profit in FY 2022)Full year 2023 results: US$0.044 loss per share (down from US$0.04 profit in FY 2022). Revenue: US$148.6m (up 11% from FY 2022). Net loss: US$16.0m (down 219% from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 9.7% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Mar 07MariMed Inc. Provides Earnings Guidance for the Full Year 2024MariMed Inc. provided earning guidance for the full year 2024. For the year, the company expects revenue growth of 5% to 7%.
New Risk • Mar 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: CA$134.1m (US$98.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (CA$134.1m market cap, or US$98.8m).
お知らせ • Feb 06MariMed Inc. to Report Q4, 2023 Results on Mar 06, 2024MariMed Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Mar 06, 2024
お知らせ • Dec 04MariMed Inc. Commences Operations of Processing Facility in Mt. Vernon, IllinoisMariMed Inc. announced it has begun manufacturing and processing cannabis products in its new processing kitchen in Mt. Vernon, Illinois. After lengthy construction and regulatory delays, the Company expects that its award-winning products will be available at dispensaries in Illinois in time for the holidays. These include MariMed's five Thrive Dispensary-branded retail locations in the state. The processing facility contains an extraction lab to produce concentrates, and a production kitchen for the manufacture of edibles and other derivative products. The cultivation facility is currently under construction in the same facility and is expected to be completed in 2024. MariMed intends to manufacture and distribute its proprietary brands and products throughout Illinois. That includes its Betty's Eddies fruit chews, which was the top-selling edible in Illinois until 2020 through a third-party licensing agreement, Bubby's Baked soft and chewy baked edibles, Vibations hydrating drink mix, InHouse gummies, K Fusion chewable tablets, and more. Upon completion of the cultivation facility construction the Company plans to commence selling its Nature's Heritage flower through retail and wholesale channels. MariMed operates five Thrive Dispensary locations in Anna, Casey, Harrisburg, Metropolis, and Mt. Vernon, Illinois.
Reported Earnings • Nov 10Third quarter 2023 earnings released: US$0.011 loss per share (vs US$0.008 profit in 3Q 2022)Third quarter 2023 results: US$0.011 loss per share (down from US$0.008 profit in 3Q 2022). Revenue: US$38.8m (up 14% from 3Q 2022). Net loss: US$4.26m (down 257% from profit in 3Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Nov 05MariMed Inc. Announces Executive ChangesMariMed Inc. announced that effective October 31, 2023, Susan M. Villare resigned as Chief Financial Officer of the Company. The Board of Directors has appointed Jon Levine, President and CEO, as the Company’s Interim Chief Financial Officer and has initiated a search process to identify and engage a new Chief Financial Officer.
お知らせ • Nov 04MariMed Inc. to Report Q3, 2023 Results on Nov 08, 2023MariMed Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023
お知らせ • Sep 14MariMed Inc. Announces its Bubby's Baked Introduces New THC-Infused Blueberry Muffin Bites to Start Day on High NoteMariMed Inc. headed to the blueberry bush to create the latest addition to its Bubby’s Baked™ THC-infused soft baked goods line of edibles. The Company’s new Blueberry Muffin bites are soft and baked in small batches, a made-from-scratch ode to breakfast. They join the popular Bubby’s Baked line inspired by the original pot brownie recipe and are available at select dispensaries in Massachusetts, Maryland, and Delaware. Each Bubby’s Baked Blueberry Muffin bite is an enticing combination of sweetness and tartness, bursting with real blueberries and infused with full-spectrum cannabis. With 35% of cannabis consumers saying they have recently enjoyed a cannabis baked good, Bubby’s Baked Blueberry Muffin bites are sure to satisfy the most discerning sweet tooth. In Massachusetts, they are precision-dosed with 5 mg of cannabis; in Maryland and Delaware, they are available with 10 mg of cannabis. The new Blueberry Muffin bites join the other three flavors in the Bubby’s Baked line-up, including classic Brownie, Choco Chip and Snickerdoodle. The Bubby’s Baked brand was inspired by the original homemade pot brownie. The brand’s classic Brownie flavor was intended to recreate and elevate the nostalgic experience so many consumers remember as their first cannabis-infused edible. Other flavors in the line include Choco Chip and Snickerdoodle.
Reported Earnings • Aug 04Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.005 profit in 2Q 2022)Second quarter 2023 results: US$0.003 loss per share (down from US$0.005 profit in 2Q 2022). Revenue: US$36.5m (up 11% from 2Q 2022). Net loss: US$958.0k (down 153% from profit in 2Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Jun 30MariMed Inc. to Report Q2, 2023 Results on Aug 02, 2023MariMed Inc. announced that they will report Q2, 2023 results After-Market on Aug 02, 2023
Reported Earnings • May 10First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.013 profit in 1Q 2022)First quarter 2023 results: US$0.002 loss per share (down from US$0.013 profit in 1Q 2022). Revenue: US$34.4m (up 9.9% from 1Q 2022). Net loss: US$645.0k (down 115% from profit in 1Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • May 09MariMed Inc. Provides Revenue Guidance for the Full Year 2023MariMed Inc. provided revenue guidance for the full year 2023. For the period, the company expects revenue of at least $150 million.
Board Change • Mar 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Eva Selhub was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 04Full year 2022 earnings released: EPS: US$0.04 (vs US$0.022 in FY 2021)Full year 2022 results: EPS: US$0.04 (up from US$0.022 in FY 2021). Revenue: US$134.0m (up 10% from FY 2021). Net income: US$13.5m (up 86% from FY 2021). Profit margin: 10.0% (up from 5.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Feb 02MariMed Inc. to Report Q4, 2022 Results on Mar 01, 2023MariMed Inc. announced that they will report Q4, 2022 results After-Market on Mar 01, 2023
Board Change • Jan 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Eva Selhub was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 15MariMed Inc. Appoints Jon Levine as Interim Chief Executive OfficerMariMed Inc. announced its Board of Directors appointed Jon Levine, MariMed’s President, as Interim Chief Executive Officer. The Board will conduct a process to identify a permanent Chief Executive Officer for MariMed, which may include external and internal candidates. The Company will announce an update on the process upon completion. No timing was provided for the duration of the process.
お知らせ • Dec 13+ 1 more updateMarimed, Inc. Announces Death of Chairman Robert FiremanMariMed Inc. announced with deep sadness that Chairman and co-founder Robert Fireman died unexpectedly on December 11, 2022.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Eva Selhub was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Nov 08MariMed Inc. Provides Earnings Guidance for Full Year 2022MariMed Inc. provided earnings guidance for full year 2022. For the year, the company expects Revenue of $132 million to $135 million.
お知らせ • Oct 13MariMed Inc. to Report Q3, 2022 Results on Nov 07, 2022MariMed Inc. announced that they will report Q3, 2022 results After-Market on Nov 07, 2022
Board Change • Oct 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Eva Selhub was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Sep 23MariMed Inc., Annual General Meeting, Oct 27, 2022MariMed Inc., Annual General Meeting, Oct 27, 2022, at 10:00 Eastern Daylight. Location: Hilton Boston/Dedham Hotel located at 25 Allied Drive Dedham, Massachusetts 02026 Dedham Massachusetts United States Agenda: To consider and approve the election of five Directors to serve until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified; to consider and approve the advisory approval of the appointment of M&K CPAs PLLC as the Company’s independent auditors for the fiscal year ending December 31, 2022; and to consider other matters.
お知らせ • Sep 08+ 2 more updatesMariMed, Inc. Announces the Availability of A New and Scrumptious Cannabis-Infused Ice CreamMariMed Inc. announced the availability of a new and scrumptious cannabis-infused ice cream. MariMed collaborated with the legendary Boston ice cream brand Emack & Bolio's® to develop and market new and innovative vegan and dairy ice cream in outrageous flavors. The ice cream is an extension of MariMed's top-selling and award-winning Betty's Eddies infused fruit chews brand and shares the brand's commitment to being hand-crafted and using all-natural ingredients. The ice cream contains MariMed's superior formulations of full spectrum cannabis oil, with natural cannabinoids and terpenes. Two delicious vegan flavors, Cup O' Coffee Chip and Chocolate Sunny Days, debuted at MariMed's Panacea Wellness dispensary in Middleborough, MA, this week. Additional flavors and wider availability are expected in the coming months.
Reported Earnings • Aug 10Second quarter 2022 earnings released: EPS: US$0.005 (vs US$0.023 in 2Q 2021)Second quarter 2022 results: EPS: US$0.005 (down from US$0.023 in 2Q 2021). Revenue: US$33.0m (up 1.3% from 2Q 2021). Net income: US$1.82m (down 76% from 2Q 2021). Profit margin: 5.5% (down from 23% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 14%, compared to a 66% growth forecast for the industry in Canada.
お知らせ • Aug 09MariMed Inc. Revises Earnings Guidance for 2022MariMed Inc. revised earnings guidance for 2022. For the period, the company now expects Revenue in the range of $135 million to $140 million versus the previous range of $145 million to $150 million.